ライフサイエンスコーパス: no evidence of disease

1 r median of 27 months; range, 8-60), 33% had no evidence of disease.

2 erapy (4) or rituximab (2) and remained with no evidence of disease.

3 etween the recurrence samples and those with no evidence of disease.

4 6% (n = 84), with 50% of patients alive with no evidence of disease.

5 n the respiratory tract, the hamsters showed no evidence of disease.

6 cted-tongue, ear, liver, and gut-also showed no evidence of disease.

7 opathologist as either normocellular or with no evidence of disease.

8 up of 36 months; four of these patients have no evidence of disease.

9 of 15 months, 19 patients were alive, 9 with no evidence of disease.

10 owed 13 patients (36%) were still alive with no evidence of disease.

11 tients, and three patients remain alive with no evidence of disease.

12 p of 2(1/2)-7 years (mean, 3.95 years), with no evidence of disease.

13 Fourteen patients (33%) show no evidence of disease (9.5 to 96 months from diagnosis)

14 -cell counts after superinfection, there was no evidence of disease acceleration.

15 Subjects with no evidence of disease activity (NEDA) by clinical and M

16 tiple sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a trea

17 ed and almost 80% of the patients have still no evidence of disease activity at the end of DMF treatm

18 , the proportion of IFN-switch patients with no evidence of disease activity increased by approximate

19 ogically; subjects were classified as having no evidence of disease, adenomatous polyps of less than

20 ntry receptors (double-knockout mice) showed no evidence of disease after inoculation by any route.

21 .6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemothera

22 ntervals to 10 cervical cancer patients with no evidence of disease after they underwent radical surg

23 treatment of the SCC lesion(s) resulting in no evidence of disease, and at least 2 months of follow-

24 The patient had no evidence of disease at a follow-up examination 1 mont

25 Two patients surgically rendered as having no evidence of disease at enrollment remain free of dise

26 Ten (56%) of 18 patients had no evidence of disease at their post-treatment cystoscop

27 remission (CR) and 3 (2 AML and 1 ALL) with no evidence of disease but failure to recover normal neu

28 e undergone a radical prostatectomy and have no evidence of disease for 5 years still have detectable

29 llected at the end of therapy when there was no evidence of disease had a relapse 5 months later.

30 After surgery, there was no evidence of disease in 78%, 25%, and 7% of patients w

31 ed disease progression) and surgical result (no evidence of disease, minimal residual disease, bulky

32 levels at presentation between patients with no evidence of disease (NED) after radiation and those w

33 two of 41 (53.7%) patients continuously show no evidence of disease (NED) and eight additional patien

34 Currently, 10 of 49 (20%) patients have no evidence of disease (NED) at a median follow-up of 39

35 The percent of patients who continuously had no evidence of disease (NED) were as follows: group A, 9

36 e 12 patients, eight patients currently have no evidence of disease (NED), and four patients died of

37 Sixteen of 47 patients continuously have no evidence of disease (NED).

38 The gastric wall was normal with no evidence of disease on EUS-guided biopsy in eight of

39 n four men, 39 of 41 (95%, 95% CI 83-99) had no evidence of disease on multiparametric MRI at 12 mont

40 In contrast, S96 mice showed no evidence of disease or generation of disease-associat

41 Patients without DLT and no evidence of disease progression after 48 weeks enroll

42 rcoma on the phase II trial of pazopanib had no evidence of disease progression at 12 weeks.

43 months, three remain alive, one of whom has no evidence of disease progression.

44 ears), five (30.4%) patients were alive with no evidence of disease (range, 1.7 to 12.8 years; median

45 Nine patients are alive with no evidence of disease recurrence at a median of 62 mont

46 y, the treatment was safely interrupted with no evidence of disease recurrence during 8-37 mo (mean,

47 adjuvant chemotherapy plus trastuzumab with no evidence of disease recurrence or metastatic disease

48 Clinical records of stage III patients with no evidence of disease seen at Memorial Sloan-Kettering

49 tients who have completed treatment and have no evidence of disease should be monitored.

50 sease compared with patients with limited or no evidence of disease, specifically physical function (

51 D plus RT significantly improved biochemical no evidence of disease survival over STAD (P < .0001) pr

52 Long-term remission with no evidence of disease was achieved only if mice were tr